By Aditya Samal (Reuters) -Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a panel meeting.
Latest posts by Crypto Editor (see all)
- Magnitude 5.5 earthquake strikes Tarapaca, Chile region – EMSC - March 25, 2023
- Man behind guns in Haitian president’s assassination pleads guilty - March 25, 2023
- Ancient Egypt excavation uncovers 2,000 mummified ram heads at Abydos - March 25, 2023